Pickleball's popularity surged, with a 311% increase in players since 2020, reaching 19.8 million in 2024. A cross-sectional ...

In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

Early pegcetacoplan treatment results in significantly greater tissue preservation compared to delayed treatment, emphasizing ...

Ken Beckman, MD, FACS, is a corneal specialist and clinical assistant professor at The Ohio State University. At the 2025 ...

A key area of practice management and sustainability initiatives is ensuring that waste is reduced whenever possible. In a ...

DAVIO-2 for wet AMD and VERONA for DME. In the DAVIO-2 trial, patients previously treated with approximately 10 injections in ...

The American Academy of Ophthalmology (AAO) is hosting its annual scientific meeting in Orlando, Florida from October 17 ...

A new study published in Experimental Eye Research reported that the preclinical results achieved with SPG302 (Spinogenix, ...

The 18-month extension of the GATHER2 trial indicated continued benefit for patients receiving avacincaptad pegol, with ...

Ahead of the 2025 American Academy of Ophthalmology (AAO) meeting, the Eye Care Network spoke with Peter Stalmans, MD, PhD, ...

The study analyzed real-world treatment patterns and safety of avacincaptad pegol (ACP) for geographic atrophy using the IRIS ...

STAAR responded by saying, “We urge all STAAR stockholders not to be misled by Broadwood. STAAR is confident that the Alcon transaction maximizes value for STAAR stockholders [and] is the only merger ...